| Literature DB >> 20003295 |
Jun Wan1, Jinben Ma, Ju Mei, Genfa Shan.
Abstract
BACKGROUND: Gene targeted therapy refers to any therapy focused on one of the many biological features of the tumor. Such features are mediated by specific genes that are involved in tumor metastasis, recurrence, poor response to chemotherapy and others. Hypoxia is an important pathognomonic feature of many malignant tumors including SCLC (small cell lung cancer). HIF-1alpha, which is induced by hypoxia, is the most important regulatory factor of many specific genes that can influence the biological features of tumors.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20003295 PMCID: PMC2797501 DOI: 10.1186/1756-9966-28-150
Source DB: PubMed Journal: J Exp Clin Cancer Res ISSN: 0392-9078
Figure 1Microarray and data analysis (A) Scatter graph of gene chip scanning signals: Scatter plot of the normalized microarray datasets resulting from analysis of human SCLC NCI-H446 cells. All 54,614 gene probes are represented in this plot. (B) Experimental design and summary of results: Text in red indicates the total number of genes upregulated in 3 experimental conditions (Ad5-HIF-1alpha vs. Ad5; Ad5 vs. Ad5-siHIF-1alpha; hypoxia vs. control-normoxia). Text in blue indicates the total number of genes downregulated in 3 experimental conditions (same as above). Finally, 65 genes were upregulated and 28 genes were downregulated in all 3 pairwise comparisons. (C) Hierarchical clustering analysis of gene expression profiles of three pairwise comparisons (Ad5-siHIF-1alpha group vs. Ad5 group1, Ad5-HIF-1alpha group vs. Ad5 group2, hypoxia group vs. normoxia group). The normalization of all the data of genes with differential expression was handled by clustering analysis using software Gene Spring 7.0. The graph of clustering analysis on the right side is the magnification about the local region (as marked by black border) of the total clustering analysis.
65 genes upregulated by HIF-1alpha more than 2.0-fold in three pairwise comparisons
| UniGeneID | Gene name | Gene Symbol | Fold change(ratio ≥ 2) | ||
|---|---|---|---|---|---|
| Ad5-HIF-1alpha/Ad5 | Ad5-siHIF-1alpha/Ad5 | Hypoxia/normoxia | |||
| Hs.351812 | C-type lectin domain family 4, member C | CLEC4C | 12.99 | -9.66 | 17.54 |
| Hs.190622 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 | DDX58 | 5.28 | -3.12 | 4.77 |
| Hs.163173 | interferon induced with helicase C domain 1 | IFIH1 | 3.73 | -2.07 | 4.15 |
| Hs.529053 | complement component 3 | C3 | 2.29 | -2.10 | 3.17 |
| Hs.655445 | chloride intracellular channel 2 | CLIC2 | 12.12 | -3.92 | 10.46 |
| Hs.257352 | apolipoprotein L, 6 | APOL6 | 8.57 | -3.98 | 7.92 |
| Hs.78036 | solute carrier family 6, member 2 | SLC6A2 | 5.28 | -4.01 | 4.79 |
| Hs.250083 | solute carrier family 9, member 2 | SLC9A2 | 2.64 | -2.19 | 3.17 |
| Hs.200738 | solute carrier family 38, member 6 | SLC38A6 | 2.46 | -2.94 | 2.86 |
| Hs.42645 | solute carrier family 16, member 6 | SLC16A6 | 2.30 | -3.16 | 4.90 |
| Hs.577463 | solute carrier family 41, member 2 | SLC41A2 | 2.32 | -4.23 | 5.19 |
| Hs.658514 | solute carrier family 12, member 8 | SLC12A8 | 2.14 | -3.01 | 3.75 |
| Hs.510939 | solute carrier family 12, member 6 | SLC12A6 | 2.12 | -2.01 | 3.41 |
| Hs.288034 | solute carrier family 39, member 8 | SLC39A8 | 2.05 | -2.92 | 4.35 |
| Hs.235782 | solute carrier organic anion transporter | SLCO4A1 | 2.05 | -2.88 | 5.12 |
| Hs.592215 | insulin receptor substrate 4 | IRS4 | 6.96 | -5.79 | 5.13 |
| Hs.20961 | G protein-coupled estrogen receptor 1 | GPER1 | 6.50 | -3.05 | 7.99 |
| Hs.75199 | protein phosphatase 2, regulatory subunit B | PPP2R5B | 3.48 | -2.51 | 6.70 |
| Hs.145404 | phosphatidylinositol-specific phospholipase C | PLCXD3 | 3.40 | -4.91 | 3.46 |
| Hs.497402 | leucine-rich repeat-containing G protein-coupled receptor 6 | LGR6 | 2.46 | -2.19 | 4.10 |
| Hs.458414 | interferon induced transmembrane protein 1 | IFITM1 | 2.29 | -3.43 | 2.86 |
| Hs.645475 | amphiregulin (schwannoma-derived growth factor) | AREG | 2.05 | -3.07 | 3.86 |
| Hs.143250 | tenascin C (hexabrachion) | TNC | 5.28 | -3.23 | 6.44 |
| Hs.2375 | egf-like module containing, mucin-like, hormone receptor-like 1 | EMR1 | 3.48 | -3.31 | 4.57 |
| Hs.415762 | lymphocyte antigen 6 complex, locus D | LY6D | 2.30 | -4.30 | 3.61 |
| Hs.479439 | protocadherin 7 | PCDH7 | 2.00 | -3.29 | 2.70 |
| Hs.2962 | S100 calcium binding protein P | S100P | 4.59 | -2.16 | 4.32 |
| Hs.332012 | immunoglobulin superfamily, member 8 | IGSF8 | 2.00 | -2.47 | 2.85 |
| Hs.73793 | Vascular endothelial growth factor-A | VEGF-A | 6.76 | -3.98 | 15.40 |
| Hs.437322 | tumor necrosis factor, alpha-induced protein 6 | TNFAIP6 | 6.96 | -4.75 | 12.17 |
| Hs.635441 | insulin-like growth factor binding protein 5 | IGFBP5 | 4.83 | -4.45 | 9.80 |
| Hs.517581 | heme oxygenase (decycling) 1 | HMOX1 | 2.64 | -2.73 | 4.58 |
| Hs.505924 | high mobility group AT-hook 2 | HMGA2 | 2.63 | -2.83 | 2.09 |
| Hs.234434 | hairy/enhancer-of-split related with YRPW motif1 | HEY1 | 2.60 | -2.15 | 3.89 |
| Hs.570855 | platelet derived growth factor C | PDGFC | 2.26 | -3.21 | 4.37 |
| Hs.497200 | phospholipase A2, group IVA | PLA2G4A | 2.14 | -2.55 | 6.67 |
| Hs.114948 | cytokine receptor-like factor 1 | CRLF1 | 2.00 | -3.05 | 4.75 |
| Hs.50640 | suppressor of cytokine signaling 1 | SOCS1 | 7.46 | -7.13 | 8.06 |
| Hs.501778 | tripartite motif-containing 22 | TRIM22 | 4.56 | -4.14 | 4.47 |
| Hs.1706 | interferon regulatory factor 9 | IRF9 | 3.73 | -2.16 | 3.90 |
| Hs.567641 | myocardin | MYOCD | 3.03 | -2.08 | 3.58 |
| Hs.655904 | zinc finger protein 277 | ZNF277 | 2.13 | -2.74 | 2.37 |
| Hs.200250 | cAMP responsive element modulator | CREM | 2.05 | -2.31 | 3.45 |
| Hs.437322 | tumor necrosis factor, alpha-induced protein 6 | TNFAIP6 | 6.97 | -6.07 | 7.39 |
| Hs.701982 | interleukin 1 receptor, type I | IL1R1 | 2.64 | -2.21 | 4.00 |
| Hs.525572 | bradykinin receptor B1 | BDKRB1 | 2.48 | -2.51 | 2.99 |
| Hs.534847 | complement component 4A (Rodgers blood group) | C4A | 2.16 | -2.03 | 2.66 |
| Hs.196384 | prostaglandin-endoperoxide synthase 2 | PTGS2 | 2.07 | -2.96 | 3.05 |
| Hs.81791 | tumor necrosis factor receptor superfamily member 11b | TNFRSF11B | 2.00 | -2.77 | 3.65 |
| Hs.203717 | fibronectin 1 | FN1 | 2.31 | -2.57 | 3.84 |
| Hs.654458 | interleukin 6 (interferon, beta 2) | IL6 | 5.29 | -2.27 | 6.10 |
| Hs.387367 | cytochrome P450, family 39, subfamily A, polypeptide 1 | CYP39A1 | 11.32 | -7.58 | 12.30 |
| Hs.460260 | aldo-keto reductase family 1, member C1 | AKR1C1 | 9.85 | -3.45 | 8.47 |
| Hs.567256 | aldo-keto reductase family 1, member C2 | AKR1C2 | 3.10 | -2.37 | 2.90 |
| Hs.116724 | aldo-keto reductase family 1, member B10 | AKR1B10 | 3.03 | -2.10 | 2.83 |
| Hs.78183 | aldo-keto reductase family 1, member C3 | AKR1C3 | 2.65 | -2.07 | 2.30 |
| Hs.419240 | solute carrier family 2, member 1 | SLC2A14 | 2.60 | -2.91 | 3.22 |
| Hs.419240 | solute carrier family 2, member 3 | SLC2A3 | 2.46 | -2.17 | 3.91 |
| Hs.572518 | UDP-glucose dehydrogenase | UGDH | 2.00 | -2.77 | 3.14 |
| Hs.160871 | protein tyrosine phosphatase, receptor type, O | PTPRO | 3.25 | -2.31 | 4.20 |
| Hs.43666 | protein tyrosine phosphatase type IVA, member 3 | PTP4A3 | 2.46 | -2.83 | 4.66 |
| Hs.497822 | dual specificity phosphatase 10 | DUSP10 | 2.14 | -3.15 | 3.02 |
| Hs.459265 | interferon stimulated exonuclease gene 20 kDa | ISG20 | 9.19 | -4.57 | 8.10 |
| Hs.118633 | 2'-5'-oligoadenylate synthetase-like | OASL | 8.00 | -4.82 | 6.26 |
| Hs.144873 | BCL2/adenovirus E1B 19 kDa interacting protein 3 | BNIP3 | 2.12 | -2.35 | 4.19 |
Figure 2Real-time PCR analysis of upregulated or downregulated gene expression in response to HIF-1alpha (A) Aliquots of the same RNA preparations used for microarray hybridization were analyzed by quantitative real-time PCR. In three pairwise comparisons, the upregulation-folds of IGFBP5, IRS4, TNFAIP6, SOCS1, IL-6, VEGF-A mRNA expression were calculated. The mean and standard error are shown (p < 0.05). (B) Aliquots of the same RNA preparations used for microarray hybridization were analyzed by quantitative real-time PCR. In three pairwise comparisons, the downregulation-folds of IGFBP3, ZNF569, SOCS2, SIRPa and XRCC4 mRNA were calculated. The mean and standard error are shown (p < 0.05).
28 genes downregulated by HIF-1alpha more than 2.0-fold in three pairwise comparisons
| UniGeneID | Gene name | Gene Symbol | Fold change(ratio ≥ 2) | ||
|---|---|---|---|---|---|
| Ad5-HIF-1alpha/Ad5 | Ad5-siHIF-1alpha/Ad5 | Hypoxia | |||
| Hs.666728 | Na+/H+ exchanger domain containing 1 | NHEDC1 | -27.86 | 9.86 | -12.33 |
| Hs.666367 | potassium voltage-gated channel, Shal-related subfamily, member 3 | KCND3 | -16.00 | 6.13 | -11.82 |
| Hs.581021 | signal-regulatory protein alpha | SIRPa | -4.93 | 3.10 | -3.72 |
| Hs.504317 | solute carrier family 16, member 14 (monocarboxylic acid transporter 14) | SLC16A14 | -4.59 | 2.46 | -4.30 |
| Hs.118695 | potassium voltage-gated channel, subfamily G, member 1 | KCNG1 | -2.13 | 2.35 | -3.17 |
| Hs.158748 | solute carrier family 35, member F3 | SLC35F3 | -2.06 | 2.76 | -2.55 |
| Hs.443625 | collagen, type III, alpha 1 | COL3A1 | -2.29 | 2.16 | -3.78 |
| Hs.458406 | undifferentiated embryonic cell | KCNG1 | -36.76 | 12.17 | -45.69 |
| Hs.511848 | zinc finger protein 569 | ZNF569 | -12.13 | 7.61 | -15.33 |
| Hs.412196 | intraflagellar transport 57 homolog | IFT57 | -8.58 | 4.38 | -7.36 |
| Hs.533977 | thioredoxin interacting protein | TXNIP | -5.28 | 3.10 | -5.01 |
| Hs.4779 | GATA zinc finger domain containing 2B | GATAD2B | -3.48 | 2.31 | -6.30 |
| Hs.9521 | zinc finger protein 92 | ZNF92 | -2.83 | 2.09 | -3.19 |
| Hs.490273 | cAMP responsive element binding | CREB3L2 | -2.07 | 2.00 | -3.12 |
| Hs.524248 | zinc finger protein 362 | ZNF362 | -2.00 | 2.67 | -4.78 |
| Hs.485572 | suppressor of cytokine signaling 2 | SOCS2 | -6.06 | 3.06 | -7.12 |
| Hs.450230 | insulin-like growth factor binding | IGFBP3 | -4.02 | 2.17 | -5.73 |
| Hs.8867 | cysteine-rich, angiogenic inducer, 61 | CYR61 | -3.03 | 2.18 | -3.77 |
| Hs.289008 | nuclear undecaprenyl pyrophosphate- | NUS1 | -2.83 | 2.13 | -4.01 |
| Hs.699288 | neural precursor cell expressed, developmentally down-regulated 9 | NEDD9 | -2.64 | 2.26 | -2.57 |
| Hs.370503 | FYN binding protein (FYB-120/130) | FYB | -6.06 | 3.97 | -4.71 |
| Hs.460355 | protein kinase C, beta 1 | PRKCB1 | -3.25 | 2.56 | -4.30 |
| Hs.390729 | v-erb-a erythroblastic leukemia viral oncogene homolog 4 | ERBB4 | -2.46 | 2.11 | -3.89 |
| Hs.654491 | receptor tyrosine kinase-like orphan receptor 1 | ROR1 | -2.47 | 2.32 | -4.56 |
| Hs.653377 | insulin-like growth factor 1 receptor | IGF1R | -2.00 | 2.89 | -3.11 |
| Hs.606356 | pleckstrin homology domain interacting protein | PHIP | -17.15 | 4.76 | -10.03 |
| Hs.567359 | X-ray repair complementing defective repair in Chinese hamster cells 4 | XRCC4 | -8.00 | 6.21 | -5.69 |
| Hs.502182 | brain-derived neurotrophic factor | BDNF | -2.30 | 2.14 | -2.18 |
Figure 3Western blot analysis of regulation of protein expression by HIF-1alpha in NCI-H446 cells. According to different treatments, all the cells were divided into four groups: control group (the cells cultured under normoxic conditions of 20% O2), Ad5-HIF-1alpha transfection group, hypoxia group (the cells cultured under normoxic conditions of 1% O2) and Ad5-siHIF-1alpha transfection group (after transfection, the cells were cultured under normoxic conditions of 1% O2). (A) Western blot analysis for IGFBP5 protein expressed by the cells of four groups. (B) Western blot analysis for SOCS1 protein expressed by the cells of four groups. (C) Densitometric analysis of the IGFBP5 and SOCS1 bands compared to the corresponding β-actin bands (*p < 0.05 expression of IGFBP5 or SOCS1 protein in Ad5-HIF-1alpha group vs. control group; ** p < 0.05 expression of IGFBP5 or SOCS1 protein in hypoxia group vs. control group; *** p < 0.05 expression of IGFBP5 or SOCS1 protein in Ad5-siHIF-1alpha group vs. control group). (D) Western blot analysis for IL-6 protein expressed by the cells of four groups. (E) Western blot analysis for STAT3 protein expressed by the cells of four groups. (F) Densitometric analysis of the IL-6 and STAT3 bands compared to the corresponding β-actin bands (*p < 0.05 expression of IL-6 or STAT3 protein in Ad5-HIF-1alpha group vs. Ad5-siHIF-1alpha group group.)
Figure 4Effect of HIF-1alpha and SOCS1 on cell growth was measured by cell counting. (A) After transfection with Ad5-SOCS1, the growth of cells was slowed but promoted after transfection with Ad5-siSOCS1(*p < 0.05 Ad5-siSOCS1 group vs. Ad5 group; **p < 0.01 Ad5-SOCS1 group vs. Ad5 group) (B) After transfection with Ad5- HIF-1alpha, the growth of cells was promoted but slowed after transfection with Ad5- siHIF-1alpha (*p < 0.01 Ad5-HIF-1alpha group vs. Ad5 group; **p < 0.01 Ad5-si HIF-1alpha group vs. Ad5 group). (C) In the Ad5-HIF-1alpha group, the growth of cells was promoted after blockade of SOCS1 by Ad5-siSOCS1 (*p < 0.01 Ad5- HIF-1alpha/siSOCS1 group vs. Ad5-HIF-1alpha group). (D) In the Ad5-si HIF-1alpha group, the growth of cells was slowed after co-transfection with SOCS1 (*p < 0.05 Ad5-siHIF-1alpha/SOCS1 group vs. Ad5-siHIF-1alpha group). (E) In the Ad5-HIF-1alpha group, the growth of cells was slowed from day 5 to day 8 as the growth curve moved right after co-transfection with SOCS1 (*p < 0.05 Ad5-HIF-1alpha group vs. Ad5-HIF-1alpha/SOCS1 group).
Figure 5We used the tunel stain to investigate the effect of HIF-1alpha and SOCS1 on cell apoptosis and the apoptosis rate was calculated in all the experimental groups. (A) The background was clear and the apoptotic NCI-H446 nucleuses were stained yellow and normal nucleuses were stain blue(tunel stain × 400) (B) The effect of HIF-1alpha and SOCS1 on apoptosis of SCLC cells after transfection for 8 d (*p < 0.05 Ad5-HIF-1alpha/siSOCS1 group vs. Ad5-HIF-1alpha group; **p < 0.05 Ad5-HIF-1alpha/siSOCS1 group vs. Ad5-siSOCS1 group; ***p < 0.01 Ad5-si HIF-1alpha/SOCS1 group vs. Ad5-siHIF-1alpha group; ****p < 0.05 Ad5-si HIF-1alpha/SOCS1 group vs. Ad5-SOCS1 group).